Neoplams

8

Review clinical trials related to Neoplams. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Effect of Pecha Kucha-Based Education on Symptom Management and Quality of Life in Patients Receiving Chemotherapy

This randomized controlled study aims to evaluate the effect of education delivered using the PechaKucha method on symptom management and quality of life in patients receiving chemotherapy. Participants will be randomly assigned to either an intervention group or a control group. Participants in the intervention group will receive individual education on symptom management during chemotherapy using the PechaKucha method. The education will be delivered as a video presentation consisting of 20 visual slides and lasting 6 minutes and 40 seconds. Participants in the control group will receive routine/standard patient education. Symptom severity and quality of life will be assessed before the education and one week after the intervention using the Edmonton Symptom Assessment System (ESAS) and the EQ-5D. The study will compare changes in symptom severity and quality of life between the intervention and control groups to determine whether PechaKucha-based education is effective in supporting symptom management and quality of life among patients receiving chemotherapy.

Participants needed: 140
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Istanbul Aydın UniversityUpdated: Aug 20, 2026Locations: 1
Eligibility criteria

Willing to participate in the study. [+2]

Being under 18 years of age. [+4]

Status: Recruiting

Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data

The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants. Indications Studied: Apparently healthy, symptom-free participants are enrolled and followed up to study the onset of new-onset diseases with special emphasis on non-communicable diseases (NCDs). Study Design: Single-country, multicenter, prospective, longitudinal survey. Objectives: The study aims to establish reference ranges of blood parameters using routine clinical blood tests and high-information-content methods, including proteomics, metabolomics and the so-called infrared molecular fingerprinting. The study also aims to identify novel biomarkers of major non-communicable diseases, including atherosclerotic cardiovascular disease, cancer, diabetes and chronic respiratory disease.

Participants needed: 15,000
Trial details
Age: 40+Biological sex: AllType: ObservationalSponsor: Center for Molecular Fingerprinting Research Nonprofit LLCUpdated: Aug 3, 2026Locations: 33
Eligibility criteria

Signed informed consent form (ICF) of the study. [+4]

Self-reported pregnancy (no test). [+27]

Status: Recruiting

One-Page Truth-Telling Aid for Cancer Disclosure

The goal of this clinical trial is to learn whether a one-page communication aid can improve communication between physicians and patients with cancer during cancer-related truth-telling consultations. The one-page aid is designed to help physicians quickly understand patients' preferences and needs before the consultation. The main questions it aims to answer are: * Does the one-page communication aid improve patients' satisfaction with how cancer-related information is explained? * Does the one-page communication aid reduce patients' emotional distress after the consultation? * Does the one-page communication aid improve physicians' confidence in communicating cancer-related information? Researchers will compare patients whose physicians receive the one-page communication aid with patients whose physicians provide usual care with a blank sheet for patients to write down questions. This comparison will help determine whether the one-page aid improves communication, emotional outcomes, and physician confidence. Participants will: * Complete questionnaires before and after the consultation * Receive either the one-page communication aid or a blank sheet, depending on their physician's group * Complete follow-up questionnaires at 3 months and 6 months after the consultation Physicians will also complete brief questionnaires about their communication confidence at baseline, 1 week after recruitment of their first enrolled patient, 3 months, and 6 months.

Participants needed: 400
Trial details
Biological sex: AllType: InterventionalSponsor: Chang Gung UniversityUpdated: Jul 28, 2026Locations: 1
Eligibility criteria

Physicians who provide clinical care for patients with cancer in participating o... [+2]

Physicians who are unable or unwilling to complete study procedures or follow-up... [+8]

Status: Not yet recruiting

Pilot Feasibility Study of a Dyadic Culinary Nutrition Intervention

This study will determine the feasibility and acceptability of a 12-week dyadic culinary nutrition program among Hispanic prostate cancer survivor/caregiver dyads using a randomized controlled trial design.

Participants needed: 40
Trial details
Age: 18-90Biological sex: AllType: InterventionalSponsor: University of ArizonaUpdated: Jul 14, 2026Locations: 1
Eligibility criteria

History of prostate cancer diagnosis at any stage (I-IV) [+9]

Cognitive difficulties that preclude answering the survey questions, that answer... [+4]

Status: Not yet recruiting

Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors

A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.

Participants needed: 420
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd.Updated: Jun 12, 2026
Eligibility criteria

Not listed

Status: Recruiting

xDRIVE for Florida-based Cancer Patients

Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).

Participants needed: 210
Trial details
Biological sex: AllType: InterventionalSponsor: First Ascent Biomedical Inc.Updated: May 19, 2026Locations: 2
Eligibility criteria

Patients with recurrent/refractory cancer patients up to age 18 (willing to sign... [+6]

Patients who do not have malignant tissue available and accessible, patients whe... [+1]

Status: Not yet recruiting

The Phase I Study of SIG001 Antibody on Cancer Therapy.

The goal of this clinical trial is to learn the safty characteristics of SIG001 Mab in cancer patients; It will also determine the Recommended Phase II dose of SIG001 Mab on cancer treatment, and pharmacological characteristics of SIG001. The main questions it aims to answer are: What is the safety and tolerability of SIG001 in patients with advanced solid tumors ? What is the Recommended Phase II dose of SIG001? What is the PK/PD characteristics of SIG001 in cancer patients? What is the antitumor activity of SIG001 in cancer patients? What is the immunogenicity of SIG001 in cancer patients? What is the relationship between the exposure/dose of SIG001 and its safety as well as clinical efficacy? What is the expression levels of potential biomarkers (such as SIG), if applicable, and analyze their correlation with drug exposure, efficacy, and safety? What is event-related endpoints such as the Duration of Response and Progression-Free Survival in patients treated with SIG001? This will be a single-armed study. Participants will: Intravenously Inject SIG001 every two weeks, for 4 weeks Visit the clinic on the 14th day, 30th day, and 90th day afer the last injection. Then visit the clinic for every 12 weeks.

Participants needed: 66
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Peking UniversityUpdated: Mar 20, 2026Locations: 1
Eligibility criteria

The subject must fully understand the requirements of this study and voluntarily... [+10]

SIG001 is administered during the washout period following previous antineoplast... [+23]

Status: Not yet recruiting

Plyometric Strength-Endurance Exercise in Breast Cancer

This study aims to compare an adapted plyometric strength-endurance exercise program with conventional strength training in women who are breast cancer survivors or currently undergoing treatment and who participate in provincial support associations. The goal is to determine whether a targeted plyometric intervention can provide additional benefits in physical and mental health outcomes. Using a cluster-randomized clinical trial design, the study will assess indicators such as functional capacity, muscle strength, fatigue levels, symptoms related to lymphedema, and overall quality of life. The findings are expected to contribute to a better understanding of how structured exercise programs can support recovery, physical function, and well-being in women affected by breast cancer.

Participants needed: 51
Trial details
Age: 18+Biological sex: FemaleType: InterventionalSponsor: University of VigoUpdated: Mar 13, 2026Locations: 1
Eligibility criteria

Women aged 18 years or older. [+7]

Active metastasis to other organs or tissues (e.g., liver, kidney, lung, brain)... [+5]